Mortality and reoperation risk after bioprosthetic aortic valve replacement in young adults with congenital heart disease

Authors

Stephanie M Fuller
Michele J Borisuk
Lynn A Sleeper
Emile Bacha
Luke Burchill
Kristine Guleserian
Michel Ilbawi, Advocate Aurora HealthFollow
Anees Razzouk
Takeshi Shinkawa
Minmin Lu
Christopher W Baird

Recommended Citation

Fuller SM, Borisuk MJ, Sleeper LA, et al. Mortality and Reoperation Risk After Bioprosthetic Aortic Valve Replacement in Young Adults With Congenital Heart Disease. Semin Thorac Cardiovasc Surg. 2021;33(4):1081-1092. doi:10.1053/j.semtcvs.2021.06.020

Affiliations

Division of Pediatric Cardiac Surgery, Advocate Children's Hospital

Abstract

Bioprosthetic aortic valve replacement (bAVR) in patients with congenital heart disease is challenging due to age, size and complexity. Our objective was to assess survival and identify predictors of re-operation. Data were retrospectively collected for 314 patients undergoing bAVR at 8 centers from 2000-2014. Kaplan-Meier estimation of time to re-operation and Cox regression were utilized. Average age was 45.2 years (IQR 17.8-71.1) and 30% were

Document Type

Article

PubMed ID

34174404